CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.

Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. · 2021

Read CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease. by Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8370411.txt.

Introduction

Williams and co-authors test the role of CD4 T cells in a mouse model of Parkinson's disease. The protein alpha-synuclein builds up in this disease and stirs the immune system. T cells enter the brain, but their exact effect was unclear.

Mice with extra alpha-synuclein in the midbrain showed more MHCII protein on brain immune cells. Interferon-gamma producing CD4 and CD8 T cells also moved in. Mice that lacked CD4 were protected from the loss of dopamine nerve cells. Blocking T cells with genetic changes or the drug fingolimod cut the immune response. The authors suggest that aiming at these T cell responses could slow the disease.

Catalog record

CREATORWilliams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8370411

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease By Gregory P Williams, Aubrey M Schonhoff, Asta Jurkuvenaite, Nicole J Gallups, David G Standaert, Ashley S Harms Published in: Brain DOI: 10.1093/brain/awab103 ABSTRACT Abstract α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripherally circulating CD4 and CD8 T cells derived from individuals with Parkinson’s disease have been shown to produce Th1/Th2 cytokines in response to α-synuclein, suggesting there may be a chronic memory T cell response present in Parkinson’s disease. To understand the potential effects of these α-syn associated T cell responses we used an α-synuclein overexpression mouse model, T cell-deficient mice, and a combination of immunohistochemistry and flow cytometry. In this study, we found that α-synuclein overexpression in the midbrain of mice leads to the upregulation of the major histocompatibility complex II (MHCII) protein on CNS myeloid cells as well as the infiltration of IFNγ producing CD4 and CD8 T cells into the CNS. Interestingly, genetic deletion of TCRβ or CD4, as well as the use of the immunosuppressive drug fingolimod, were able to reduce the CNS myeloid MHCII response to α-synuclein. Furthermore, we observed that CD4-deficient mice were protected from the dopaminergic cell loss observed due to α-syn overexpression. These results suggest that T cell responses associated with α-synuclein pathology may be damaging to key areas of the CNS in Parkinson’s disease and that targeting these T cell responses could be an avenue for disease modifying treatments. Keywords: Parkinson disease, alpha-synuclein, T cells, neuroinflammation INTRODUCTION Neuroinflammation is an established component of Parkinson's disease, the most common neurodegenerative movement disorder affecting an estimated 1 million individuals in the USA alone.1 The neuroinflammatory hallmarks of Parkinson’s disease include reactive CNS myeloid cells,2,3 T cell infiltration into the CNS,4,5 and increased pro-inflammatory cytokines/chemokines in the blood, CSF, and brain parenchyma of patients with Parkinson’s disease.6-8 In terms of the T cell response associated with Parkinson’s disease, several studies have shown an overall decreased amount of circulating T cells in Parkinson’s disease patients,9–11 but an increase in pro-inflammatory T cell subsets over regulatory ones.10,12,13 Recent work has indicated that alpha-synuclein (α-syn), the key pathological protein dysfunctional in Parkinson’s disease, can serve as an activator of these circulating T cells.14–16 However, the link between α-syn pathology, T cells, and how these interactions contribute to the overall neuroinflammation and neurodegeneration observed in Parkinson’s disease remains unclear. Antigen presentation via the major histocompatibility complex [MHC, human leukocyte antigen (HLA) in humans] and subsequent T cell interrogation is a process that has evolved to detect and eliminate pathogens. Through the interaction of factors including genetic predisposition and previous infections, this immune process can become dysfunctional and contribute to disease. For example, T cells have been shown to play a pivotal role in the establishment and severity of the debilitating CNS disease multiple sclerosis. During disease, T cells can misrecognize self-CNS antigens (i.e. myelin) and mount an immune response that uses the innate immune response against cells harbouring those antigens.17 It is possible that a similar process could be occurring in Parkinson’s disease in response to α-syn or some other CNS antigen as genetic analyses of Parkinson’s disease cohorts have identified polymorphisms and haplotypes of the HLA region that are associated with disease risk.18–20 Using an adeno-associated viral model to overexpress α-syn (AAV-SYN) in the substantia nigra pars compacta (SNpc) of mice, we have previously shown an important contribution of major histocompatibility complex II-positive (MHCII+) CNS myeloid cells to the α-syn-induced neuroinflammatory and neurodegenerative phenotypes.21,22 In those studies, we also observed an influx of T cells into the midbrains of α-syn-expressing mice, but their contribution to the model was not further investigated. To evaluate the role of T cells in the response to α-syn overexpression in the CNS, we used the AAV-SYN mouse model, several lines of genetically modified mice with defects in T cells, pharmacological inhibition of T cells, and a combination of immunohistochemistry/flow cytometry. We found that in the AAV2-SYN model, both CD4 and CD8 T cells infiltrate into the CNS parenchyma. Additionally, we observed that knockout or pharmacological inhibition of T cells, specifically CD4 T cells, was able to reduce MHCII expression on CNS myeloid cells as well as protect against TH+ neuron loss in the ipsilateral SNpc. The data presented here support a critical role for T cells in α-syn induced neurodegeneration, and suggests there may be potential in the use T cell immunotherapies as a treatment for Parkinson’s disease and other synucleinopathies. MATERIALS AND METHODS Mice In this study, we used male and female C57BL/6 (#000664 Jackson Laboratories), Tcrb−/− (B6.129P2-Tcrbtm1Mom/J, #002118 Jackson Laboratories), Cd4−/− mice (B6.129S2-Cd4tm1Mak/J, #002663 Jackson laboratories), and Cd8−/− mice (B6.129S2-Cd8atm1Mak/J, #002665 Jackson Laboratories); mice were maintained on a congenic background. All research conducted on animals was approved by the Institutional Animal Care and Use Committee at the University of Alabama at Birmingham. AAV2-virus Construction, purification, and validation of the original recombinant (r)AAV vectors, rAAV-CBA-IRES-EGFP WPRE (CIGW) and rAAV-CBA-SYNUCLEIN-IRES-EGFP-WPRE (CISGW) are described in previous publications.23–25 The CIGW and CISGW rAAV vectors used in this study were manufactured by the University of Iowa Viral Vector Core. Stereotaxic surgery Stereotaxic surgery performed on male and female C57BL/6 (wild-type), Tcrb−/−, Cd4−/−, and Cd8−/− mice was in accordance with previously described protocols.21,22,26 In brief, mice were deeply anaesthetized with a mixture of oxygen/isoflurane and unilaterally (immunohistochemistry and stereology) or bilaterally (flow cytometry) injected with 2 µl of AAV2-GFP or AAV2-SYN [2.6 × 1012 viral genomes/ml diluted in sterile phosphate-buffered saline (PBS)] into the SNpc at a rate of 0.5 µl/min, a rest time of 2 min, and a withdraw time of 2 min. Stereotaxic coordinates used for the SNpc were anterior-posterior −3.2 mm from bregma, mediolateral ±1.2 mm from midline, and dorsoventral −4.6 mm from dura. All surgical procedures and postoperative care protocols were followed and approved by the Institutional Animal Care and Use Committee at the University of Alabama at Birmingham. Immunohistochemistry At 4 or 26 weeks post-viral transduction animals were deeply anaesthetized and transcardially perfused with a heparinized PBS solution, followed by 4% paraformaldehyde (PFA) and PBS solution. Brains were post-fixed for 6 h or overnight in 4% PFA/PBS and then cryoprotected in a 30% sucrose solution in PBS for 48 h. Brains were then frozen on dry ice and cryosectioned coronally on a sliding microtome with a cut thickness of 40 µm. Sections were collected serially throughout the SNpc, placed into a tissue collection solution (50% PBS/50% glycerol), and stored at −20°C until immunohistochemical staining. For fluorescent staining, free-floating sections were washed in Tris-buffered saline (TBS), blocked in 5% of appropriate serum, and then labelled with anti-tyrosine hydroxylase (TH) (clone: EP1536Y, Abcam), anti-alpha-synuclein (phospho-serine129, pSer129, clone EP1536Y, Abcam), anti-GFAP (clone: D1F4Q, Cell Signaling), anti-Iba1 (polyclonal, Wako), anti-MHCI (clone: 28-14-8, eBioscience), anti-MHCII (clone: M5/114.15.2, eBiosciences), anti-CD68 (clone: FA-11, Bio-Rad), anti-CD3 (clone 17A2, eBioscience), anti-CD4 (clone RM4-5, BD Bioscience), anti-CD8 (clone 4SM15, eBioscience), or anti-IgG (polyclonal, Jackson Laboratories) antibodies in TBS plus Triton (TBS-T), lightly shaking overnight at 4°C. The next day, appropriate Alexa-conjugated secondary

Read the complete text